Home

  • Meet the Author: I. Glenn Cohen

    Meet the Author: I. Glenn Cohen

    I. Glenn Cohen is the James A. Attwood and Leslie Williams Professor of Law at Harvard Law School, as well as Deputy Dean and Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics. He’s one of the world’s leading experts on the intersection of bioethics and the law, as well as health law, and a prolific contributor to working papers on SSRN. In a wide ranging interview with SSRN he shared his thoughts on some fascinating issues at the intersection of health and law, from the recent Alabama Supreme Court ruling on the legal status of embryos, to the ethical and legal issues raised by AI, and some extraordinary new developments in reproductive science.

    Q: For people who may not be familiar with the term, what does it mean to be a bioethicist?

    A:  Like many fields the borders are porous and precise definitions contested, but in general I think a fair definition of bioethics is that it “the interdisciplinary study of ethical issues arising in the life sciences, health care, and health science and policy.” It looks as the spaces where the medical system raises ethical questions – questions of right or wrong – which blend into questions of policy. Bioethics had its roots in religious studies and philosophy and medical practice, so at the start of the field (dated by most people to the 1960s) most people came in from that tradition. Over time more law people, more medical people, empirical people, political science, sociology, and critical studies approaches have come in, among others, so it’s now a pretty interdisciplinary field.

    The field studies everything from clinical medical decision making, which, to policy questions about rationing COVID-19 vaccines, to questions about the scientific process, questions about the ethical conduct of human clinical trials and even whether certain kinds of diseases ought to get priority in terms of being researched.

    Q: What issue did the recent Alabama ruling on embryos raise for you, and do you think it could lead to a federal ban on abortion in the US?

    A:  As it happens, I’ve got a preprint relevant to this on SSRN for a book that came out this week, I wrote the paper maybe a year and a half ago, and I will hopefully have a paper coming out shortly, probably after this is published, on the Alabama case specifically, so it’s something I’ve thought about a lot.

    There is a narrow legal question posed by the Alabama case, and a broader, cultural philosophical question.

    The narrow legal question is whether, under the statute that provides for tort liability for the wrongful death of a minor – which allows people to sue someone who causes the wrongful death of a minor, – whether that statute is used for the word minor, or child, or person, does it apply only to children who were born, or does it apply to embryos that are being stored in a freezer?

    The bigger question is part of the context of a larger set of political forces and philosophical issues. The political forces have been, I think, galvanised by the reversal of Roe v. Wade in the United States, which provided an abortion right protected by the Federal constitution. In the Dobbs case, the Supreme Court said, “No, we’re going to say the constitution does not provide such a right, and that States are now free to make policy in this area.” With that kind of victory at hand, the anti-abortion movement, or portions of it, has set their sight on a new goal which is not to return the matter to the States, but instead to have a nationwide ban on abortion.

    One way of achieving that is to get the recognition, ideally at the level of the Federal constitution, that foetuses, and perhaps now embryos, are persons –  such that their destruction violates the constitution, and such that a state action that permits the destruction of foetuses – even in states that are Democrat-leaning like Massachusetts where I live – would not be able to have an abortion protective law in place. That’s the political arc, and decisions like this are an important piece of it.

    The philosophical question is a difficult one, which is to say: when does personhood begin? That’s just a different question than the question, “When does life begin?” or “When does being a human being begin?” One could have different answers to all three questions, and indeed, in the book chapter that I have up on SSRN as a preprint, I discuss prevailing differences of opinion as to whether embryos are a person.

    I think the questions about the morality of embryo destruction are in some ways more far reaching than the question about the morality of abortion. The reason I say this is because you can believe that abortion ought to be lawful and permitted, while still believing the foetuses are persons that deserve the protection that persons normally get: because you think women’s reproductive rights, their autonomy over their bodies, and control of one’s body is so important that it even permits women to engage in an activity which caused the destruction of a developing, or emerging person.

    In the case of embryo destruction, we don’t have the same kind of countervailing interests around controlling our bodies. Instead, the countervailing interest is, one, about controlling what happens to the embryos we create, or having a right to create embryos that we will destroy in the end, and these seem to me to be weaker countervailing rights claim , which sets very directly the question about when does personhood begin in early embryo persons.

    Q: You did a TED talk a while ago in which you discussed what it is to be a human and what it is to be a person, and it struck me that the court in this case said clearly “This embryo is a person: they’ve just gone straight there.”  And as you say, it’s a tougher hill to die on than abortion, because there is less conflict around other people’s interests.

    A: The questions around what a person is are fascinating, I’m so glad you saw the TED talk. I was talking a little bit about animal personhood, there are also questions about AI personhood that are now emerging, and to have a robust theory of personhood that explains A but not B, is philosophically challenging. Often, the prevailing theories of personhood have implications we don’t like. The Alabama case is asking narrow questions on a particular statute, but it’s a harbinger, I think, of things to come.

    One of the Chief Justices of Alabama’s Supreme court had a concurring opinion full of explicitly religious language references, Bible discussions about how this offends God because we’re created in his image, and the idea of God’s holy wrath. It also raises the question in a larger political context, about to what extent our legislative acts or judicial decisions are permitted to invoke explicitly religious terms, or not, and that of course is a big debate too.

    Q: It seems like our clever colleagues in technology are keeping bioethicists busy in reproductive health, particularly with IVF, artificial wombs, and the reverse engineering of fertility cells from other human tissue; are there technological developments in this field that you think will be raising interesting questions in the future?

    A: I would say all the above… There are questions about creating artificial wombs, now mostly used to transfer very early prematurely born neonates and sustain them, outside the womb after birth. Maybe one day, we could perhaps have them starting gestation in artificial wombs. This raises all sorts of questions about whether you have a right to do this or can be prevented from doing this.

    Uterus transplants are happening in many parts of the world already, and thinking about those, do you have a right to experience pregnancy that is separate from the right to be a parent? So, if someone says, “Well you could use a surrogate?”, can you say, “No, actually I want to carry in my own womb,” or really, a borrowed womb. This idea of transplanted uteruses also raises interesting questions about how we think about the uterus donors. What are their relationships to the child that’s born? Should the State pay for this, is this a want, or a medical need?

    I talk to transplant surgeons and there is no reason to think male uterus transplantation is biologically impossible. We could also in the future perhaps transplant uteruses onto the male pelvis, either to people who are assigned male at birth and live as men, or to people assigned male at birth who have transitioned and are living their lives as women. Essentially the idea would be that you might make a claim that a person has a right to experience pregnancy as someone who was assigned male at birth, and does the State have an obligation to pay for that?

    In vitro gametogenesis is the potential to derive sperm and egg from adult cells, and we’ve done this successfully in mice and dogs. There are companies now trying to perfect this in human beings too. There’s a lot of reasons why this might not happen scientifically or regulatorily, but essentially there are interesting questions about whether same sex couples, for example, should have a rights claim to use In vitro gametogenesis to produce a child that is both of their genetic lineage; so from sperm and egg, one of which being derived from the person in the relationship that normally doesn’t do that, so an egg derived from our males adult skin cells, and a sperm derived from a woman’s adult stem cells.

    There is also the possibility of true genetic single parenthood, where you provide both the sperm and the egg. There is the idea of Multiplex parenthood, which would be, for example taking sixteen people fand deriving an embryo from each of them and then deriving from that sperm and egg, and then putting it together and so on and so forth. So, collapsing what we normally think of as the pathway from our great-great- grandparents to us, which usually happens over multiple generations, into a single generation. Why would you want to do that is unclear, but it’s an interesting question that pushes the boundaries beyond the more traditional, ‘reproductive technologies’, such as IVF, surrogacy, sperm provision, sperm donations and the like. So, the ethical and legal questions abound, which is one of the reasons why I love working in this field.

    Q: AI is the current big technology breakthrough. At the end of your SSRN paper on ChatGPT, you write about the need for ethicists as gadflies to ensure companies do the right thing. What should a good gadfly do in this space?

    A: I think this is very interesting because I am asked sometimes to give ethical advice or legal advice in this space. My view is, your responsibility is not to future-proof things, because it turns out that the like the famous Yogi Berra quote says, “it’s very hard to make predictions, especially about the future.” I think you need to really press on questions and viewpoints that might not otherwise come to the table, especially in the product development cycle, which obeys certain kinds of imperatives and incentives.

    I do not think it is a a horrific fact that corporations don’t necessarily always operate by the same values or viewpoints that I may have as an ethicist: That is, I am not appalled that corporations are going to corporate.  But, it should be incumbent upon them, and if not incumbent upon them then incumbent upon outside forces to push them, to really have this pressure-testing to say, “What could go wrong, but also, “What could go right?”

    We don’t always think about successes and the way successes could create ethically problematic settings; I think about this in the healthcare space I work in. For privacy, often we think about the error that somebody will get the wrong impression about me and make the wrong inference about me from partial information. One of the biggest threats from AI is that it becomes *too good* at making the correct inferences about me and about my future health state.

    Insurance works for all of us because we operate under conditions of uncertainty, whereas if I could exactly predict what your future costs would be, it would be the kind of thing that might destroy the insurance process because we couldn’t cross subsidise. So, there are ways in which it is not just our failures, but our successes we must think about. We should at least pose the questions and bring to bear different perspectives, and it’s a helpful thing when they are brought into a conversation, rather than merely being on the outside criticising after the fact.

    Q: Just as a worked example of how AI might impact journalism, when I asked ChatGPT: ‘If you were going to interview Prof Glenn Cohen in the Wall St Journal, what would be some interesting and intellectually challenging legal questions that you could ask him?’ I got: “Ethical implications of emerging medical technologies; legal challenges in global health crises; reproductive rights; artificial intelligence; legal and ethical issues in healthcare; access and inequality; regulatory challenges and medical tourism; AI and law practise and surrogacy and reproductive justice.” It’s not bad…

    A: Not bad at all…

    Q: One of the big issues for publishers is the issue of training AI with copyrighted material. How do you see that challenge for copyright holders for training?

    A: I have very smart colleagues who are thinking about that, and I view myself as an amateur here. But putting aside whether the law declares there’s a copyright violation or not, let’s ask ourselves the question; do we think that something is owed in a deeper sense?

    I often make this point within the medical space that if you build an amazing algorithm or device that helps detect cancer much earlier, or helps do a better job of sorting benign versus malignant cancer tumours in a much less invasive way,  and you do this based on data collected from people across the United States, or across the world, what are your ethical obligations once you have built it? What about equitable access for all those people. If not, what are you going to do to provide that?

    I often say (borrowing a phrase from my friend and co-author Nicholson Price) that much of the value of medical AI is democratising the expertise we already have, rather than taking the expertise we have and making it even better. Dermatologists in the United States might become very good with AI augmented dermatology and that’s great, but when I think about all the people across the world, and across the US, that don’t have the opportunity to see a dermatologist, and I think by taking the expertise of just an average, or even a below average dermatologist and scaling that up, it seems ethically the really attractive value proposition.

    We’re only going to get that if the incentives to develop AI, to build AI, to disseminate AI, align with that. So, I think that people often talk about the alignment problem in AI and making AI a kind of, a sorcerer’s apprentice, I think there’s an even bigger alignment problem, which is the alignment between what AI is getting built for, and what it has value for in an ethical sense.

    Q: How have you seen this stuff affect your students and other researchers work? I have had some interesting conversations with my son about his university essays and students all seem to be making their peace with the fact that this is very often a tool that, just like Google, is a part of their research – although that may be a benign explanation of what they’re doing…

    A: We have the benefit of being an extremely well-resourced university with very smart people who are ahead of the curve, such that, even when Open AI and Chat GPT debuted, there were many people around these parts who knew a lot about it, even at the very beginning, and had given some thought before much of the craze became public. As a result, I think there is a predictable reaction phasing and we’ve been able to move through it a little quicker.

    So, the First Phase is just, “Oh my gosh, what just happened, this is going to change everything I need to do, we need to run to get academic policies and concerns about cheating, and what will be our policy on this”” etc.

    The Second Phase, I think, is this idea of, “This is so interesting…” We can observe and run a bunch of experiments and see what’s working, see what’s helpful in the educational space and see what our students are doing, both in the settings we observe them, but also, for example, as our law students in their summers; we can ask what are the law firms doing, and how are they dealing with that?

    I think we’re still in the second phase, but transitioning to the Third Phase, which is to think that of all those costs or uses: which are the ones that are corrosive to what we want to achieve in education, which are the ones that are exciting and successful, and which are the ones that we want to be creative with and think about integrating?

    I give an example of our flagship course for people learning computer science; for this course, I understand them to have built a tutor or bot that has rules about what it will answer, and what it won’t answer. In a way, that could scale feedback much more effectively than only using teaching fellows, that’s an exciting use case. What about the ability for students to generate brand-new exam questions, in the mode of the kinds of exam questions I would ask, but that are not my exam questions, and then being able to critique answers as practise? That’s exciting and useful.

    I don’t want to suggest that all the concerns about cheating are something we should ignore, there’s still lots of questions within education and medicine about deep fakes, about watermarking, and that is the current conversation among the big tech companies, in part because they try to avoid actual regulation, so they’re trying to self-regulate this space.

    The decision to unveil ChatGPT, and the other labs, in the way they did, in the moment they did, was a hugely costly endeavour for most educational institutions. To suddenly have to scramble, learn, protect against, and deal with this, when I think about this idea of redistribution, effort, and time to introduce a product that has all of these impacts for the world, I wonder, what’s your obligation before you release it to work with those communities, socialise those communities, and also have the fixes ready to go for their issues?

    I can tell you the standard plagiarism detectors, for example, are not always that good on ChatGPT. I do think it raises a question about political economy, that large tech companies do what they do, and the people who have to pay for it indirectly might be poorly funded public schools, and the educators there; teachers who are under-compensated here in the United States, scrambling and trying to figure this out, and that’s an interesting case study in itself for the ethics of product launch.

    Q: You were practicing law in the government for the dept of justice. There is a huge difference between making legal policy and studying law academically. Why for you has the pull of academia been more powerful?

    A: I loved my time at the Justice Department, I was born in Canada, a Canadian citizen. To say, ‘Glenn Cohen on behalf of the United States of America your honour’, in Court was this crazy amazing thing, a huge amount of pressure and exciting too.

    Why make the switch? I think there is basically two reasons, for me at least, one is the ability to choose the projects that interest me as opposed to doing the work of the government, which is incredibly important but what is important to the government on a particular day and its overlap with my area of interest may be small.

    The second reason was as a litigator I was often, if not always, in an adversarial position where my view is, “The government’s right, we’re going to win, or “Our position’s not so great, so can I figure out how to settle this case?” But it’s essentially a constantly adversarial position, us against other people, whereas for me, I really also enjoy a little bit more of a constructive relationship, particularly with my students, the ability to foster, to mentor, to support, and to learn from them. That is incredibly exciting and enriching and that is probably the main thing that caused me to make this switch.

    Q: Law has always been one of the most important disciplines for SSRN, how do you think about SSRN in the context of legal scholarship?

    A: SSRN has become a huge hub for legal scholarship, especially via the subject matter journals that many view as one of the best ways to keep up. We are blessed that law reviews tend to be open access by default, such that SSRN often ends up carrying not just pre-prints but final versions of articles too. Especially in fast-moving areas (like the recently Supreme Court litigation over the approval of the drug Mifepristone for early abortions or Trump’s ballot eligibility) the drafts that go up on SSRN are vital for educating the public and the bar since the cases may be resolved before the publication cycle of the actual paper concludes.

    Q: If people wanted to learn more about your research, are there any books or papers that you’ve shared on SSRN or elsewhere recently that would be a good start for them?

    A: To my surprise I apparently have 129 scholarly papers on SSRN, so I am a frequent flyer!I am not sure if I am a good judge of quality, but here are a few to look at that might be interesting regarding things in the news.

    On how to think about the current controversy over embryo personhood, perhaps this book chapter by me: (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4284007),

    For early thoughts on bioethics and ChatGpt just as it was getting out the gate,

    (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4430100)

    For how to think about liability for artificial intelligence in medicine this co-authored book chapter:

    (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4115538)

    And for learning about state attempts to regulate the therapeutic and non-therapeutic use of psychedelics, in this case focused on micro dosing, this recent co-authored paper: (https://papers.ssrn.com/sol3/papers.cfm?abstract_id=4544500)


  • Five of the most downloaded law papers posted on SSRN in 2023

    Five of the most downloaded law papers posted on SSRN in 2023

    It’s time for a round up of 2023! We’ve been thinking about which are some of the hottest papers across different networks at SSRN, and what sort of topics they cover.

    First up is our Legal Scholarship Network (LSN). We’ve picked out five of the papers with the most downloads, and noted the focus on the interaction of AI and law, and how ChatGPT might affect law education going forward. We’ve included some in our selection, as well as a few others on various law topics. Check out the papers below!

    ChatGPT Goes to Law School

    Jonathan H. Choi, Kristin E. Hickman, Amy Monahan, Daniel Schwarcz

    How well can AI models perform on law school exams without human assistance? The abstract discusses a study where an AI model, ChatGPT, was used to write answers for law school exams at the University of Minnesota. The results showed that ChatGPT performed at the level of a C+ student, obtaining passing grades in all four courses, and the implications for legal education and writing are discussed, along with advice on how ChatGPT can assist in legal writing.

    The Sweep and Force of Section Three

    William Baude, Michael Stokes Paulsen

    Section Three of the Fourteenth Amendment prohibits former officeholders from holding office if they participate in insurrection or rebellion, but this article argues that its full legal impact has been overlooked. This article clarifies that Section Three is still valid, immediately disqualifies individuals from office without needing Congress’ action, supersedes prior constitutional rules, and could disqualify former President Donald Trump and others involved in attempting to overturn the 2020 presidential election.

    AI Tools for Lawyers: A Practical Guide

    Daniel Schwarcz, Jonathan H. Choi

    This article offers advice to lawyers and law students on how to use advanced AI models like GPT-4 in legal research and writing. It suggests that by applying traditional legal skills to refine and verify AI-generated legal analysis, individuals can turn these models into valuable personal legal assistants.

    Trading on Terror?

    Robert J. Jackson, Jr., Joshua Mitts

    Recent research shows that traders are disguising their trades in certain types of financial assets like ETFs. By examining the behavior of financial markets during military conflicts, the study finds a significant increase in short selling in Israeli-company ETFs just before the October 7 Hamas attack. This suggests that some traders may have had advance knowledge of the attack and profited from it, highlighting gaps in enforcement of laws against insider trading.

    GPT-4 Passes the Bar Exam

    Daniel Martin Katz, Michael James Bommarito, Shang Gao, Pablo Arredondo

    This paper tests the performance of an early version of GPT-4 on the Uniform Bar Examination (UBE), which includes multiple-choice questions and open-ended essays. GPT-4 shows significant improvement over previous models, scoring higher than human test-takers in some areas and surpassing the passing threshold for all UBE jurisdictions, suggesting its potential in supporting legal services.

    You can read all of our papers on the Legal Scholarship Research Network here.

  • ORCIDs From Amsterdam…

    ORCIDs From Amsterdam…

    Last week SSRN’s CEO Gregg Gordon joined the rest of the ORCID leadership team for the ORCID Board meeting in Amsterdam, and also hosted a meeting between ORCID and Elsevier at the company HQ in Amsterdam’s Radarweg office.

    If you’re not familiar with ORCID’s work, ORCID, which stands for Open Researcher and Contributor ID, is a global, not-for-profit organisation supported by fees from organisations such as Elsevier in the scholarly communications space. It’s community-built and governed by a board of directors designed to represent a wide range of stakeholders who care about identity in scholarship. Gregg joined the board last year and will serve until the end of 2025.

    A small group in person in the office and a much larger group online via Zoom were able to hear the latest news from the ORCID team in a session hosted by former Elsevier tech guru Chris Shillum, who now leads ORCID as Executive Director. The team shared ORCID’s vision to establish a unique identifier for people who contribute to the scholarly record, so that their work can be correctly connected to their contributions “across disciplines, borders, and time.”

    ORCID tries to do this by providing three pieces of infrastructure for scholarship: The first is the ORCID identifier itself, which is a unique free-of- charge ID for researchers. The second is the ORCID profile which is a digital CV for scholars, allowing them to share details of their employment, education, funding, and other metadata with the rest of the world. Finally ORCID has a set of APIs to enable interoperability between an ORCID record and ORCID’s member organisations.

    In the presentation at Elsevier, Chris and the team shared ORCID’s strategic priorities for this year, which include increasing the value it offers to member and researchers, getting more people to participate with ORCID, and a new goal around upholding trust which aims to address the current crisis in scholarly integrity.

    The team fielded lots of questions from different Elsevier folks keen to learn more about their work and how we can best support ORCID in our products and it was nice to see Chris back on familiar turf, as it’s several years since he was last in the Elsevier office.
    You can learn more about ORCID’s work here, and below you can see the ORCID Board braving a particuarly cold February day before the board meeting – Gregg needed that scarf…

  • SSRN and the Financial Times on the Impact of Academic Research

    SSRN and the Financial Times on the Impact of Academic Research

    SSRN has again collaborated with the Financial Times, this time to provide data on the impact of business school academics’ research.

    SSRN provided the FT with information to identify popular business school research papers by the download counts from ‘practitioners’. In this case, this means downloads by users in positions of influence, including users from commercial and central banks, regulators and local and national government agencies.

    You can read the whole report by the FT here, which includes a summary of the most downloaded business school papers.

  • Announcing New Article Page Branding for Research Paper Series

    Announcing New Article Page Branding for Research Paper Series

    SSRN is thrilled to announce a new feature for Research Paper Series (RPS). The innovative release applies institutional branding to every article page associated with papers of a Research Paper Series, allowing authors and institutions to better highlight their work.

    What’s this about?

    A Research Paper Series promotes the research output of authors from an institution, for example George Mason, collected nicely together on a customized landing page. A Research Paper Series will often focus on a specific part of an institution, such as a law school, business school, and a department within a corporation. Applying institutional branding on all articles included in a Research Paper Series strengthens the presence of an institution and underscores an author’s work. 

    Why Have we Made this Change?

    Institutionally branded article pages enable discovery of a Research Paper Series on SSRN more easily than ever before. Prior to this new feature, an author’s participation in a Research Paper Series was noticeable through a clickable series identifier found under the paper title on the article page. With this new release, the institutional branding for all authors of a paper (displaying up to four different RPS branding, ordered alphabetically) will appear at the top of the article page, linking back to the associated Research Paper Series. It’s an excellent mechanism for authors to emphasize their affiliation as well as creating a more visible and interconnected scholarly network. 

    We’re really excited to make this change to provide more value to our RPS customers – we’re very proud to showcase their support for so much of the great research on SSRN, and we’ll continue to explore creative ways to add value to their work,” said Michael Magoulias, SSRN’s Director of Operations.

    You can see an example of this new feature by clicking on a paper in the Antonin Scalia Law School, George Mason University, Law & Economics Research Paper Series.

  • Science Direct and SSRN: Joining the dots between the preprint and the Version of Record

    Science Direct and SSRN:  Joining the dots between the preprint and the Version of Record

    SSRN and Science Direct have joined forces to help researchers get easier access to the latest version of the research paper they’re searching for.

    We’ve set up a new link so that if a researcher finds an SSRN preprint in Google Search or Google Scholar and they’re entitled to access a version of record of that paper, they’ll be automatically taken to the most recent published version on Science Direct of the article they were searching for. If the reader is still keen to see the preprint version, there’s a prominent link back to the preprint version on SSRN for them.

    We’ve made these change in collaboration with our colleagues at Science Direct to try and address one of the big challenges in Scholarly Communications – how can we join the dots between the different stages of the evolution of a piece of research, from working paper to accepted manuscript to version of record? It can be tough to understand which version of a research paper you’re looking at, and even harder to know if a more up to date version is available. This change creates a living link between the preprint and the Version of Record, as our user research consistently shows this is something the research community is really keen to see.

    Below is an example of the new flow when you search for the SSRN working paper you’re looking for on Google Scholar or Google Search…

    …If you have access to the article on Science Direct, you’ll be taken straight to the published version of the article there. (If you don’t have access, you’ll be taken to the SSRN page as normal.)

    If you still want to check out the preprint from SSRN, you can easily navigate to the SSRN article page by clicking on the SSRN link, which is highlighted below…

    Similarly, if you’re on the SSRN article, and want to navigate to the Science Direct article, you can find a link, highlighted below.

    For any SSRN preprint that does not have a later, published version, the user will still be taken to SSRN to access the preprint. Similarly, if a preprint does have a published version, but the user does not have access to it on ScienceDirect, they will not be redirected to the published version.

    We hope that this change is helpful for people looking for the most up to date version of the paper they’re entitled to, and we’re going to continue exploring ways to make it easier for people to understand which version of the research paper they’re reading and how it connects to other versions of that paper. For instance, we will be exploring how we can work with other publishers to also provide links to their VORS on other platforms. If you have any questions, or have thoughts about this change, you can reach out to us at ideas@ssrn.com.

  • Social Media for Researchers

    Social Media for Researchers

    As part of our collaboration with Researcher Academy, we’re bringing you useful information about all things research.

    The latest video helps researchers to make the most of social media to promote their work, meet other researchers and exchange results.

    Dr. Christian DeFeo Product Marketing Manager of Mendeley – Social explains the history of social networking for researchers, the benefits of each platform type and how you can use them to your advantage.

    Video doesn’t work? You can find it here. You’ll also be able to access any downloadable content and post comments. 

    You can find more information and more videos about all stages of the research process, from funding though to presenting your research to a larger audience, on Researcher Academy’s website.

  • Being positive about the negative…

    Being positive about the negative…

    Being Positive about the Negative…
     
    As part of Elsevier, SSRN’s Product and Content teams are committed to doing what we can to support research integrity, so we’ve been exploring ways to encourage authors across different disciplines to share negative and null results from their experiments and research – and today we’re announcing a new experiment with the launch of a new Special Topic Hub for Negative and Null Results.

    This article on Elsevier Connect, “Why it’s time to publish research “failures”, provides some great context on the importance of sharing negative results to mitigate the bias in research towards positive results. For SSRN, negative results – in which an experiment fails or a hypothesis is proven false – are an important part of the scholarly record. By helping others avoid repeating your negative results, sharing research failures saves the wider research community valuable time and resources. However, negative results tend to attract less interest than positive results and are often hard to place in peer reviewed journals and other scientific platforms in which people are looking for new results that will make a splash and have high impact. This means interesting or useful negative results may not get the exposure they deserve.

    We’ve been polling authors on SSRN and via our social media channels about the importance of negative results, and we have received lots of interest in making it easier to share research with negative results; the majority of people we polled said that it was important to share negative results as they’re an important part of the scientific record.

    We’ve launched the new Negative Results Special Topic Hub, organised by scientific discipline, as part of a experiment to see what happens when we provide a new home for authors who want to share their negative and null results with us.

    We’re going to be tracking papers volumes and exploring different ways to market the hub to different scholarly communities.

    Note: This experiment ended on Wednesday April 17th 2024 and the Negative Results Hub is now closed, many thanks to everyone who submitted papers,

  • SSRN Authors win Nobel prizes

    SSRN Authors win Nobel prizes

     It’s that time of year again where the Nobel prizes are announced. The Nobel prizes mark an annual recognition of a person’s (or persons) contribution to the benefit of humankind in the preceding year. They fall into five categories: literature, physics, chemistry, physiology or medicine and peace. In 1968, Sweden’s Central bank established an additional prize, the Sveriges Riksbank Prize in Economics Science, in memory of Alfred Nobel, the entrepreneur and businessman, who left his fortune in 1895 to the establishment of the prizes.

    SSRN, Elsevier’s preprint and early research sharing platform is very honoured that among this year’s Nobel laureates are 2 SSRN authors: Drew Weissman, (Penn Institute for RNA Innovations, University of Pennsylvania, Philadelphia, PA, USA) wins jointly with Katalin Karikó (Szeged University, Szeged, Hungary; University of Pennsylvania, Philadelphia, PA, USA) in the category of physiology or medicine for discoveries concerning nucleoside base modifications that enabled the development of effective mRNA vaccines against COVID-19. Their collaborative work reportedly started after a chance meeting at a photocopier in 1997. We’re all familiar with the Pfizer and Moderna mRNA COVID-19 vaccines, their (seemingly superhuman) rapid development and roll out globally and the relief that it brought in allowing lockdowns to be lifted and our emergence from the pandemic. Dr Weissman has posted a number of papers on SSRN including one that investigated the broad neutralising effects of a nanoparticle vaccine against various SARS-CoV-2 (the COVID-19 virus) variants, including Omicron.

    Claudia Goldin, a prolific SSRN author, wins the Sveriges Riksbank Prize in Economic Sciences for her formative work in advancing our understanding of women’s labour market outcomes.

    SSRN congratulates all winners in all categories; we celebrate the benefits to humankind that these gifted individuals have brought. And finally, no Nobel blog could be complete without revisiting the most heartwarming and brilliant reaction from Doris Lessing on winning the Literature Prize in 2007.

    Images Credit: Ill. Niklas Elmehed © Nobel Prize Outreach 

  • Life after publication: How to promote your work for maximum impact

    Life after publication: How to promote your work for maximum impact

    As part of our collaboration with Researcher Academy, we’re bringing you useful information about all things research.

    The latest video helps researcher to understand how to promote their work for maximum impact. It can be difficult to make sure your research doesn’t fall through the cracks, but instead stands out.

    This video covers topics such as how to ensure your research appears high on the lists of results returned by search engines, and how to promote your work even before it’s finished.

    Video doesn’t work? You can find it here. You’ll also be able to access any downloadable content and post comments. 

    You can find more information and more videos about all stages of the research process, from funding though to presenting your research to a larger audience, on Researcher Academy’s website.